Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?
Chemotherapy-induced thrombocytopenia (CIT) is the most important cause of thrombocytopenia in cancer patients. In this paper, I discussed the effect of ABO blood group on CIT in patients with stage III colon cancer. In a pilot study, a total of 131 (72 men, 55 %) eligible patients with stage III colon cancer were divided into two groups according to whether they had CIT. Both groups were compared using demographic, histopathological, and laboratory variables. CIT was detected in 51 (40 %) of 131 patients. The incidence of CIT had a significant increased in patients with 0 blood group compared to other blood groups. It was concluded that the relationship between blood group 0 and the presence of CIT in patients with stage III colon cancer is independent of other study variables (P = 0.035, OR 3.14, 95 % CI 1.16-7.01). In conclusion, I hypothesized that 0 blood group may predict to differentiate high-risk patients for CIT.